CellaVision AB (publ) (STO:CEVI)

Market Cap	4.67B
Revenue (ttm)	747.94M
Net Income (ttm)	152.12M
Shares Out	23.85M
EPS (ttm)	6.38
PE Ratio	30.67
Forward PE	25.90
Dividend	2.50 (1.28%)
Ex-Dividend Date	May 7, 2025

Volume	16
Average Volume	30,258
Open	196.00
Previous Close	195.60
Day's Range	196.00 - 196.00
52-Week Range	147.80 - 302.00
Beta	1.23
RSI	63.76
Earnings Date	Apr 29, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers, instruments; and hardware products include in vitro diagnostics IVD for laboratories; as well as its portfolio includes smear makers, stainers, stains, and staining protocols; DIFF-Line is a hematology lab that handles a smaller amount daily blood samples and consists three instruments for smearing, staining, and analyzing ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 219
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.